iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABOS) - The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F
2α receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF
2α is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin. Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights.
ObsEva SA: ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
ePoster
, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha (PGF
2
a) antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation (SRI) 68
th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.
Presentation details
are as follows:
Abstract ID: W-063
Session
Session Time: 4:00-5:30 p.m. ET
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Skip to main content
Currently Reading
Shady Grove Fertility (SGF) Welcomes Reproductive Endocrinologist, Emily Barnard, D.O., to the Washington, D.C. and Towson Physician Teams
PRWeb
FacebookTwitterEmail
WASHINGTON (PRWEB) March 01, 2021
Shady Grove Fertility (SGF) is proud to announce that reproductive endocrinologist, Emily Barnard, D.O., has joined the practice and will begin seeing patients at SGF’s Washington, D.C. - K Street and Towson offices in April 2021. Dr. Barnard will provide a full range of state-of-the-art, in-house diagnostic and treatment options for female and male infertility, elective egg freezing, LGBTQ family building, and fertility preservation prior to cancer treatment.